% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • racavalli racavalli May 3, 2013 10:38 AM Flag

    misleading article today

    Today's article in Seeking Alpha didn't help Ampio's case at all because the article was botched up with careless and unfounded comments such as Ampion's approval will take longer than investors realize. What the author did not realize is that this these are pivotal Phase III trials. They may take a little longer because of the additional run in study but not to the extent the author implies.

    The article also errs tremendously in the statement that Optina may take some of the Eylea and Lucents sales for DME. Optina is in trials for DME specifically. Optina is a pill. Eylea and Lucentis are brutal injections directly into the eyeball. They are expensive running close to $2,000 per treatment. Eylea and Lucentis have serious adverse side effects. Now consider that Optina has NO SIDE EFFECTS, is less costly and is A PILL.

    That would suggest to any reasonable thinking person that Optina will not just take a few sales away, but it will CRUSH Eylea and Lucentis making them obsolete overnight.

    If Optina is approved, REGN is a hug money making short.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.7466+0.0288(+4.01%)Oct 20 4:02 PMEDT